Helicobacter pylori is the primary etiologic agent involved in gastric diseases in humans with worldwide distributions. In 2005, H. pylori was identified as a microbiologic contaminant of water, and its role in gastric diseases was further assessed.
Longitudinal studies of Helicobacter pylori infection acquisition during early childhood with diagnosis established by locally validated noninvasive tests are scarce, particularly at high risk populations.
Helicobacter pylori is a putative risk factor for peptic ulcers and gastric cancer. Current treatment guidelines for H pylori are based on results from developed countries.
In Guatemala, gastric cancer (GC) presents some of the highest rates of incidence and mortality in the world.
Chile has a 60 to 80 % rate of Helicobacter infection depending on the region; is no surprise that the mortality rate due to gastric cancer in Chile is one of the highest in America.
Little is known about serum diagnostic metabolites relate to H. pylori risk of gastric cancer (GC). We aimed to investigate the association between plasma metabolite concentrations and H. pylori infection and two cohorts of patients at risk and excluded GC.
